Etorphine increases the number of μ-opioid receptor-positive cells in the cerebral cortex

M. Melone, N. C. Brecha, C. Sternini, C. Evans, F. Conti

Research output: Contribution to journalArticle

Abstract

Imunocytochemical techniques were used to determine whether agonist-induced activation of μ-opioid receptors alters the number and distribution of μ-opioid receptor-positive cells in the rat cerebral cortex. In untreated rats, μ-opioid receptor immunoreactivity was localized to neuronal perikarya and dendrites and to neuropilar punctate structures. μ-Opioid receptor-positive neurons were mostly in layers II and III and exhibited a bipolar or bitufted morphology. In rats treated with the μ-opioid receptor agonist etorphine (0.1mg/kg intraperitoneally) and perfused after different survival periods, there was an enhancement of immunostaining for μ-opioid receptors observed at 15min, reaching a maximum at 60min, and which returned to normal at 480min. Etorphine-induced effects included an increase in the intensity of cellular and neuropil staining; statistical analysis showed that the number of μ-opioid receptor-positive cells in etorphine-treated groups was significantly higher than in controls or saline-treated rats. In animals that received both etorphine and the μ-opioid receptor antagonist naloxone, the pattern of μ-opioid receptors immunoreactivity was similar to that of untreated animals.This study shows that the number of μ-opioid receptor-positive cells is significantly increased following etorphine treatment and suggests that agonist treatment may be exploited to increased immunostaining of μ-opioid receptors and also of other G-protein coupled receptors. Copyright (C) 2000 IBRO.

Original languageEnglish
Pages (from-to)439-443
Number of pages5
JournalNeuroscience
Volume100
Issue number3
DOIs
Publication statusPublished - Sep 27 2000

Fingerprint

Etorphine
Opioid Receptors
Cerebral Cortex
Neuropil
Narcotic Antagonists
Naloxone
G-Protein-Coupled Receptors
Dendrites

Keywords

  • Immunocytochemistry
  • Neurons
  • Opiate
  • Rats

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Etorphine increases the number of μ-opioid receptor-positive cells in the cerebral cortex. / Melone, M.; Brecha, N. C.; Sternini, C.; Evans, C.; Conti, F.

In: Neuroscience, Vol. 100, No. 3, 27.09.2000, p. 439-443.

Research output: Contribution to journalArticle

Melone, M. ; Brecha, N. C. ; Sternini, C. ; Evans, C. ; Conti, F. / Etorphine increases the number of μ-opioid receptor-positive cells in the cerebral cortex. In: Neuroscience. 2000 ; Vol. 100, No. 3. pp. 439-443.
@article{2f5b65065f924c26829367dba021b900,
title = "Etorphine increases the number of μ-opioid receptor-positive cells in the cerebral cortex",
abstract = "Imunocytochemical techniques were used to determine whether agonist-induced activation of μ-opioid receptors alters the number and distribution of μ-opioid receptor-positive cells in the rat cerebral cortex. In untreated rats, μ-opioid receptor immunoreactivity was localized to neuronal perikarya and dendrites and to neuropilar punctate structures. μ-Opioid receptor-positive neurons were mostly in layers II and III and exhibited a bipolar or bitufted morphology. In rats treated with the μ-opioid receptor agonist etorphine (0.1mg/kg intraperitoneally) and perfused after different survival periods, there was an enhancement of immunostaining for μ-opioid receptors observed at 15min, reaching a maximum at 60min, and which returned to normal at 480min. Etorphine-induced effects included an increase in the intensity of cellular and neuropil staining; statistical analysis showed that the number of μ-opioid receptor-positive cells in etorphine-treated groups was significantly higher than in controls or saline-treated rats. In animals that received both etorphine and the μ-opioid receptor antagonist naloxone, the pattern of μ-opioid receptors immunoreactivity was similar to that of untreated animals.This study shows that the number of μ-opioid receptor-positive cells is significantly increased following etorphine treatment and suggests that agonist treatment may be exploited to increased immunostaining of μ-opioid receptors and also of other G-protein coupled receptors. Copyright (C) 2000 IBRO.",
keywords = "Immunocytochemistry, Neurons, Opiate, Rats",
author = "M. Melone and Brecha, {N. C.} and C. Sternini and C. Evans and F. Conti",
year = "2000",
month = "9",
day = "27",
doi = "10.1016/S0306-4522(00)00307-9",
language = "English",
volume = "100",
pages = "439--443",
journal = "Neuroscience",
issn = "0306-4522",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Etorphine increases the number of μ-opioid receptor-positive cells in the cerebral cortex

AU - Melone, M.

AU - Brecha, N. C.

AU - Sternini, C.

AU - Evans, C.

AU - Conti, F.

PY - 2000/9/27

Y1 - 2000/9/27

N2 - Imunocytochemical techniques were used to determine whether agonist-induced activation of μ-opioid receptors alters the number and distribution of μ-opioid receptor-positive cells in the rat cerebral cortex. In untreated rats, μ-opioid receptor immunoreactivity was localized to neuronal perikarya and dendrites and to neuropilar punctate structures. μ-Opioid receptor-positive neurons were mostly in layers II and III and exhibited a bipolar or bitufted morphology. In rats treated with the μ-opioid receptor agonist etorphine (0.1mg/kg intraperitoneally) and perfused after different survival periods, there was an enhancement of immunostaining for μ-opioid receptors observed at 15min, reaching a maximum at 60min, and which returned to normal at 480min. Etorphine-induced effects included an increase in the intensity of cellular and neuropil staining; statistical analysis showed that the number of μ-opioid receptor-positive cells in etorphine-treated groups was significantly higher than in controls or saline-treated rats. In animals that received both etorphine and the μ-opioid receptor antagonist naloxone, the pattern of μ-opioid receptors immunoreactivity was similar to that of untreated animals.This study shows that the number of μ-opioid receptor-positive cells is significantly increased following etorphine treatment and suggests that agonist treatment may be exploited to increased immunostaining of μ-opioid receptors and also of other G-protein coupled receptors. Copyright (C) 2000 IBRO.

AB - Imunocytochemical techniques were used to determine whether agonist-induced activation of μ-opioid receptors alters the number and distribution of μ-opioid receptor-positive cells in the rat cerebral cortex. In untreated rats, μ-opioid receptor immunoreactivity was localized to neuronal perikarya and dendrites and to neuropilar punctate structures. μ-Opioid receptor-positive neurons were mostly in layers II and III and exhibited a bipolar or bitufted morphology. In rats treated with the μ-opioid receptor agonist etorphine (0.1mg/kg intraperitoneally) and perfused after different survival periods, there was an enhancement of immunostaining for μ-opioid receptors observed at 15min, reaching a maximum at 60min, and which returned to normal at 480min. Etorphine-induced effects included an increase in the intensity of cellular and neuropil staining; statistical analysis showed that the number of μ-opioid receptor-positive cells in etorphine-treated groups was significantly higher than in controls or saline-treated rats. In animals that received both etorphine and the μ-opioid receptor antagonist naloxone, the pattern of μ-opioid receptors immunoreactivity was similar to that of untreated animals.This study shows that the number of μ-opioid receptor-positive cells is significantly increased following etorphine treatment and suggests that agonist treatment may be exploited to increased immunostaining of μ-opioid receptors and also of other G-protein coupled receptors. Copyright (C) 2000 IBRO.

KW - Immunocytochemistry

KW - Neurons

KW - Opiate

KW - Rats

UR - http://www.scopus.com/inward/record.url?scp=0034721510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034721510&partnerID=8YFLogxK

U2 - 10.1016/S0306-4522(00)00307-9

DO - 10.1016/S0306-4522(00)00307-9

M3 - Article

C2 - 11098106

AN - SCOPUS:0034721510

VL - 100

SP - 439

EP - 443

JO - Neuroscience

JF - Neuroscience

SN - 0306-4522

IS - 3

ER -